Labcorp Holdings Inc. · NYSE:LH
Labcorp — Investor Day (September 2026)
88 slides from Labcorp's investor day presentation, Sep 10, 2026
Slide 1: ©2026
©2026 Labcorp. All rights reserved.
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
2©2026 Labcorp. All rights reserved. Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance, the long-term financial outlook, and the long-term capital
Slide 3: Use of Adjusted Measures
3©2026 Labcorp. All rights reserved. Use of Adjusted Measures The company has provided in this presentation “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted EPS (or adjusted net income per share), adjusted operating margin, and free cash flow. M
Slide 4: 2026 Agenda
4©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. Agenda Opening Dewey Steadman Welcome Adam Schechter Diagnostics Bryan Vaughn Biopharma Laboratory Services Dr. Brian Caveney BREAK Specialty Diagnostics Dr. Shak Ramkissoon Technology and Innovation Dr. Bola Oyegunwa Long-Term F
Slide 5: Investor Day 2026
5©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved.
Slide 6: Welcome
6©2026 Labcorp. All rights reserved. Adam Schechter Chairman and Chief Executive Officer Welcome
Slide 7: Laboratory insights have never been more important
7©2026 Labcorp. All rights reserved. Labcorp has never been more important Laboratory insights power better health, breakthrough therapies, and personalized care to improve outcomes and build a more sustainable healthcare system
Slide 8: Healthcare is entering a new era
8©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. Healthcare is entering a new era Growing and aging population Personalized medicine advancing quickly Consumers taking on their wellness and health Advanced technology transforming healthcare Novel science and innovation driving
Slide 9: Market forces magnify the importance of Labcorp
Market forces magnify the importance of Labcorp As healthcare becomes More data-driven More personalized More technology enabled More consumer-friendly Laboratory services and insights are even more essential for Wellness and prevention Early disease detection Treatment selection Therapy monitoring
Slide 10: Labcorp is ready for this moment
10©2026 Labcorp. All rights reserved. Labcorp is ready for this moment 2026 Labcorp. All rights reserved.
Slide 11: Labcorp is a global leader in laboratory services
11©2026 Labcorp. All rights reserved. An interconnected ecosystem where insights, partnerships, scientific expertise, and innovation reinforce one another, creating a differentiated competitive advantage Labcorp is a global leader in laboratory services DIAGNOSTICSBIOPHARMA LABORATORY SERVICES Early
Slide 12: An experienced, focused, mission-driven team
12©2026 Labcorp. All rights reserved. Amy Summy Chief Marketing Officer Adam Schechter Chairman and Chief Executive Officer Anita Graham Chief Human Resources Officer Brian Caveney, MD President, Biopharma Laboratory Services and Chief Medical and Scientific Officer Jon Meltzer, PhD Chief Operations
Slide 13: Science and innovation with global scale
13©2026 Labcorp. All rights reserved. Science and innovation with global scale 1,2001 Scientists and physicians 1,000 Publications and presentations 6,500 Tests on our menu 100+ Innovative tests launched/year >50 Major laboratories globally 85% FDA drug and therapeutic product approvals supported 75
Slide 14: Trusted partner to customers across the health ecosystem
14©2026 Labcorp. All rights reserved. Trusted partner to customers across the health ecosystem1 1. Figures except Hospitals and Health Systems acquisitions and Managed Care renewal rates are rounded. 2. Based on 2025 internal sales data. 3. Payer renewal figure is from 2025-July 2026. 4. Figure repr
Slide 15: Utilizing advanced technology to power innovation and drive performance
15©2026 Labcorp. All rights reserved. Utilizing advanced technology to power innovation and drive performance Improving Customer Experiences Enhancing Productivity Transforming Our Business
Slide 16: Strategic priorities focus on high-growth areas
16©2026 Labcorp. All rights reserved. Strategic priorities focus on high-growth areas
Slide 17: Labcorp's strategic priorities focus on high-growth areas
17©2026 Labcorp. All rights reserved. Lead in specialty testing Drive personalized health solutions Be the partner of choice for health systems and leading pharma Shape our future through innovation and technology, including AI and robotics Labcorp’s strategic priorities focus on high-growth areas
Slide 18: Our long-term outlook is compelling
18©2026 Labcorp. All rights reserved. Our long-term outlook is compelling Long-Term Outlook 2026 – 2029 CAGR 5% - 8% REVENUE MARGIN EXPANSION ADJUSTED EPS GROWTH FREE CASH FLOW bps 75 - 150 CAGR 8.5% - 11.5% In line with adjusted earnings growth
Slide 19: Key takeaways
19©2026 Labcorp. All rights reserved. Key takeaways Consistent track record of delivering strong performance Tremendous growth opportunities ahead A differentiated platform powered by science, technology and global scale Compelling long-term outlook
Slide 20: Diagnostics: The next era of healthcare runs on diagnostic insights
©2026 Labcorp. All rights reserved. Diagnostics: The next era of healthcare runs on diagnostic insights Bryan Vaughn President, Diagnostics I N V E S T O R D A Y 2 0 2 6
Slide 21: Diagnostics Overview
21©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. D I A G N O ST I C S Overview Large and growing market opportunity backed by proven track record Differentiated scale and network, amplified by technology Multiple pathways for sustainable growth Positioned to lead as science an
Slide 22: Meaningful growth opportunity in a large, growing industry
22©2026 Labcorp. All rights reserved. Meaningful growth opportunity in a large, growing industry D I A G N O S T I C S $90B+ 58% 26% 4% 12% Hospital LabsOther Independent Labs Physician Office Labs Annual growth rate 1% - 3% MARKET TAILWINDS U.S. DIAGNOSTICS INDUSTRY SIZE1 Demographic trends drive d
Slide 23: Track record of above-market revenue growth
23©2026 Labcorp. All rights reserved. KEY DRIVERS OF SUSTAINED PERFORMANCE Track record of above-market revenue growth D I A G N O S T I C S Test and accession volume growth Organic expansion and strategic M&A Shift towards specialty testing Diversified payer and channel mix DIAGNOSTICS REVENUE GROW
Slide 24: A differentiated network connecting healthcare
24©2026 Labcorp. All rights reserved. A differentiated network connecting healthcare D I A G N O S T I C S We inform what's next in healthcare through... 175M+ patient interactions annually 750M tests performed annually 22M Logistics stops per year 100+ Innovative tests launched / year 90% U.S. live
Slide 25: Amplifying our impact through technology and insights
25©2026 Labcorp. All rights reserved. Amplifying our impact through technology and insights D I A G N O S T I C S BETTER EXPERIENCES SMARTER OPERATIONS • Patient and provider AI agents • Optimized patient access • Seamless digital engagement • Optimized logistics network • Automated specimen flows •
Slide 26: Driving growth through specialty, partnerships and M&A, and consumer-centric solutions
26©2026 Labcorp. All rights reserved. Driving growth through specialty, partnerships and M&A, and consumer-centric solutions
Slide 27: Specialty innovation accelerates growth, insights, and patient impact
27©2026 Labcorp. All rights reserved. Specialty innovation accelerates growth, insights, and patient impact D I A G N O S T I C S 1. H1 2026 revenue annualized. 2. Percentage growth rates are 2022-2025 revenue CAGR; includes organic and inorganic growth; figures are rounded. 3. Compared to Labcorp’s
Slide 28: M&A and partnerships drive meaningful, sustainable growth
28©2026 Labcorp. All rights reserved. M&A and partnerships drive meaningful, sustainable growth D I A G N O S T I C S California Oregon $900M in revenue from over 30 deals1 1. Reflects acquired revenue from 2023-2025; figures rounded.
Slide 29: Delivering value for health system partners
29©2026 Labcorp. All rights reserved. Renewals & service excellence Reference & lab management expertise Digital & analytics experiences Innovative collaborations Delivering value for health system partners D I A G N O S T I C S Insight Analytics Health Systems Leadership Hub Lab management expertis
Slide 30: Consumer-centric experiences broaden access to care
30©2026 Labcorp. All rights reserved. Consumer-centric experiences broaden access to care D I A G N O S T I C S DECENTRALIZE DIAGNOSTICS AND EXPAND ACCESS SIMPLIFY DIGITAL EXPERIENCES PARTNER WITH CONSUMER- FORWARD COMPANIES GROW CONSUMER TESTING
Slide 31: Delivering value and impact through integrated care partnerships
31©2026 Labcorp. All rights reserved. Delivering value & impact through integrated care partnerships D I A G N O S T I C S “What began as a trusted partnership, including critical collaboration during the COVID-19 pandemic, has evolved into a strategic relationship that advances diagnostics, oncolog
Slide 32: Key takeaways
32©2026 Labcorp. All rights reserved. Key takeaways Large, growing market supported by long-term tailwinds Technology amplifies the power of our scale, infrastructure and diagnostics expertise Multiple growth opportunities across specialty diagnostics, partnerships and consumer-centric solutions Har
Slide 33: Biopharma Laboratory Services: Powering the future of drug development
©2026 Labcorp. All rights reserved. Biopharma Laboratory Services: Powering the future of drug development I N V E S T O R D A Y 2 0 2 6 Brian Caveney, MD President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
Slide 34: Biopharma Laboratory Services Overview
34©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. B I O P H A R M A L A B O R AT O R Y S E R V I C E S ( B L S ) Overview Advancing innovation from discovery to commercialization Strong financial track record and outlook, with favorable market tailwinds Fully integrated drug de
Slide 35: Advancing innovation from discovery to commercialization
35©2026 Labcorp. All rights reserved. Advancing innovation from discovery to commercialization B I O P H A R M A L A B O R A T O R Y S E R V I C E S 1. All figures are for 2025, rounded. 2. Includes journal articles, abstracts, posters, peer-reviewed publications and presentations. Shared expertise
Slide 36: Strong track record of growth targeting a large global market opportunity
36©2026 Labcorp. All rights reserved. BLS REVENUE GROWTH Strong track record of growth targeting a large global market opportunity B I O P H A R M A L A B O R A T O R Y S E R V I C E S MARKET TAILWINDS Strong R&D Pipelines Increasing Trial Complexity Globalization of Trials Expansion of Specialty Th
Slide 37: Case study: BLS delivers measurable outcomes for trial sponsors
37©2026 Labcorp. All rights reserved. Case study: BLS delivers measurable outcomes for trial sponsors B I O P H A R M A L A B O R A T O R Y S E R V I C E S Trusted partner for leading pharma and biotech companies for 40 years ACCELERATED CLINICAL DEVELOPMENTREDUCED COMPLEXITY HIGH-QUALITY DATA
Slide 38: Integrated platform delivering comprehensive laboratory services for clinical trials
38©2026 Labcorp. All rights reserved. Integrated platform delivering comprehensive laboratory services for clinical trials B I O P H A R M A L A B O R A T O R Y S E R V I C E S Global Client Delivery organization effectively oversees all aspects of operations Results reporting Receipt at central lab
Slide 39: Competitive advantages today. Positioned to lead tomorrow.
39©2026 Labcorp. All rights reserved. Competitive advantages today. Positioned to lead tomorrow. B I O P H A R M A L A B O R A T O R Y S E R V I C E S 1. Source: FDA NME. 2. Source: Citeline, Evaluate pharma, Alzheimer’s Association. 3. Source: Labcorp internal metrics, 2025. 5 Central Labs - United
Slide 40: BLS and Diagnostics: Complementary strengths, greater client value
40©2026 Labcorp. All rights reserved. BLS and Diagnostics: Complementary strengths, greater client value B I O P H A R M A L A B O R A T O R Y S E R V I C E S Increased trial protocol complexity and data-rich requirements align well with Labcorp’s capabilities 1. Represents an annual metric. Source:
Slide 41: Key takeaways
41©2026 Labcorp. All rights reserved. Key takeaways Global leader with market tailwinds and competitive differentiation Unique scientific enterprise spanning discovery, development and commercialization Long-term partnerships driving revenue growth and margin expansion Laboratory innovation and scal
Slide 42: Break
42©2026 Labcorp. All rights reserved. Break
Slide 43: Specialty Diagnostics: Transforming innovation into access
©2026 Labcorp. All rights reserved. Specialty Diagnostics: Transforming innovation into access I N V E S T O R D A Y 2 0 2 6 Shak Ramkissoon, MD, PhD Senior Vice President, Enterprise Oncology and Diagnostics Medical Affairs
Slide 44: Specialty Diagnostics Overview
44©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. S P E C I A LT Y D I A G N O S T I C S Overview A proven engine translating innovation into real-world impact Leading in high-growth specialty areas; oncology deep dive Unifying the healthcare ecosystem to expand access to preci
Slide 45: A continuous cycle of innovation and insights powering specialty diagnostics
45©2026 Labcorp. All rights reserved. A continuous cycle of innovation and insights powering specialty diagnostics S P E C I A L T Y D I A G N O S T I C S DISCOVER AND DEVELOP Biomarker insights that unlock opportunities for novel diagnostics and precision therapies 1 DELIVER REAL-WORLD IMPACT Impro
Slide 46: Accelerating specialty leadership in high-impact therapeutic areas
46©2026 Labcorp. All rights reserved. NEUROLOGY Leading innovation in neurological diagnostics Expanding access to biomarker-driven care ONCOLOGY Deep Dive WOMEN’S HEALTH Delivering personalized insights across life stages AUTOIMMUNE Advancing precision management for chronic conditions Accelerating
Slide 47: Neurology: Leading blood-based innovation across many neurological conditions
47©2026 Labcorp. All rights reserved. S P E C I A L T Y D I A G N O S T I C S Neurology | Leading blood-based innovation across many neurological conditions Parkinson’s, ALS, and movement disorders Autoimmune neuro and MS Epilepsy and pediatric genetic disorders Concussion and TBI Stroke Migraine Al
Slide 48: Autoimmune: Advancing precision care for chronic conditions
48©2026 Labcorp. All rights reserved. Rheumatoid arthritis S P E C I A L T Y D I A G N O S T I C S SELECT CONDITIONS Diagnostic and disease activity Therapeutic drug monitoring Monitoring and surveillanceLupus Sjögren’s Disease Myositis 1. Abend AH, He I, Bahroos N, et al. Estimation of prevalence o
Slide 49: Women's Health: Delivering personalized insights across life stages
49©2026 Labcorp. All rights reserved. Women’s Health | Delivering personalized insights across life stages S P E C I A L T Y D I A G N O S T I C S 1. Spencer JC et al., Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45–64 Years, JAMA Network Open (2026), based on 2024 BRFSS da
Slide 50: Oncology Deep Dive
50©2026 Labcorp. All rights reserved. Oncology Deep Dive
Slide 51: Cancer care has dramatically evolved, but access to therapies remains a challenge
51©2026 Labcorp. All rights reserved. Cancer care has dramatically evolved over the years, but access to therapies remains a challenge S P E C I A L T Y D I A G N O S T I C S people in the U.S. living with history of cancer 18M new cancer diagnoses globally per year 20M of patients with advanced can
Slide 52: Accelerating patient access to precision therapies to improve outcomes
52©2026 Labcorp. All rights reserved. At the intersection of diagnostics and care delivery, Labcorp accelerates patient access to precision therapies to improve outcomes S P E C I A L T Y D I A G N O S T I C S DISCOVER AND DEVELOP of U.S. FDA-approved oncology therapies in 2025 were supported by our
Slide 53: Broad test menu spanning the continuum of care across indications
53©2026 Labcorp. All rights reserved. Broad test menu spanning the continuum of care across indications enables a holistic view of the patient’s disease to inform treatment decisions S P E C I A L T Y D I A G N O S T I C S PRECISION ONCOLOGY • Tissue-based molecular tumor profiling • Hereditary canc
Slide 54: Customer-driven innovation that advances care, simplifies workflows and drives durable growth
54©2026 Labcorp. All rights reserved. Customer-driven innovation that advances care, simplifies workflows and drives durable growth
Slide 55: Defining the next generation of oncology care
55©2026 Labcorp. All rights reserved. Defining the next generation of oncology care S P E C I A L T Y D I A G N O S T I C S Genome-wide analysis (DNA + RNA) Predictive algorithms TISSUE MOLECULAR PROFILING Whole genome sequencing Heme MRD HEME MALIGNANCY PROFILING Biomarker screening Predictive algo
Slide 56: Plasma Detect Genome MRD
56©2026 Labcorp. All rights reserved. Labcorp Plasma Detect Genome MRD 14-day turnaround for baseline testing for earlier treatment optimization S P E C I A L T Y D I A G N O S T I C S Only 10% - 20% of patients benefit from adjuvant chemotherapy, underscoring the need for better risk stratification
Slide 57: Plasma Detect Genome MRD are prognostic and improve current risk stratification
57©2026 Labcorp. All rights reserved. Results from Labcorp Plasma Detect Genome MRD are prognostic and improve current risk stratification S P E C I A L T Y D I A G N O S T I C S Alarcon et al., Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treate
Slide 58: Advancing MRD detection to identify recurrence earlier and inform care sooner
58©2026 Labcorp. All rights reserved. Advancing MRD detection to identify recurrence earlier and inform care sooner S P E C I A L T Y D I A G N O S T I C S Assay enhancements Ultrasensitive sequencing chemistry Improved bioinformatics Plasma Detect Genome MRD DETECTS 50 PPM1 Plasma Detect Genome MRD
Slide 59: Plasma Detect Genome MRD Ultra
59©2026 Labcorp. All rights reserved. Labcorp Plasma Detect Genome MRD Ultra S P E C I A L T Y D I A G N O S T I C S A differentiated WGS platform built for scale, adoption and patient impact Colon Stage II - III Lung Stage I - III Head & Neck Stage II - IV Muscle-invasive Bladder Stage II - III Ova
Slide 60: Key takeaways
60©2026 Labcorp. All rights reserved. Key takeaways Deep insights bridging innovation, diagnostics and care delivery to expand access to personalized therapies A comprehensive portfolio positioned in high-growth specialty markets with durable long-term growth potential A differentiated ecosystem acc
Slide 61: Technology and Innovation: Shaping what's next in healthcare
©2026 Labcorp. All rights reserved. Technology and Innovation: Shaping what’s next in healthcare Bola Oyegunwa, PhD Chief Information and Technology Officer I N V E S T O R D A Y 2 0 2 6
Slide 62: Technology and Innovation Overview
62©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. T E C H N O L O G Y A N D I N N O V AT I O N Overview Technology is reshaping what’s possible in healthcare Labcorp is embedding advanced technology across the business Technology is creating simpler, more connected customer exp
Slide 63: Diagnostics and BLS are poised for transformation
63©2026 Labcorp. All rights reserved. Diagnostics and Biopharma Laboratory Services are poised for transformation T E C H N O L O G Y A N D I N N O V A T I O N Advanced technologies will accelerate breakthroughs in Labcorp's core businesses Drug development acceleration Identification of new therapi
Slide 64: Labcorp embeds advanced technologies across our business
64©2026 Labcorp. All rights reserved. Labcorp embeds advanced technologies across our business T E C H N O L O G Y A N D I N N O V A T I O N Technology is improving customer experiences, enhancing productivity and transforming operations IMPROVING CUSTOMER EXPERIENCES Revenue growth ENHANCING PRODUC
Slide 65: Enhancing the provider experience to improve patient care
65©2026 Labcorp. All rights reserved. Enhancing the provider experience to improve patient care T E C H N O L O G Y A N D I N N O V A T I O N Reducing administrative burden and enabling faster, more informed clinical decisions Support clinical decision making Empower care decisions with insights and
Slide 66: Empowering people with personalized, connected care experiences
66©2026 Labcorp. All rights reserved. Empowering people with personalized, connected care experiences T E C H N O L O G Y A N D I N N O V A T I O N MyLabcorp makes accessing, managing, and navigating care simple and intuitive Provide patient education Empowers care discussions through accessible hea
Slide 67: Enabling faster study execution and better trial outcomes
67©2026 Labcorp. All rights reserved. Enabling faster study execution and better trial outcomes T E C H N O L O G Y A N D I N N O V A T I O N Accelerating end-to-end study execution through digital workflows, intelligent automation and operational insights Digitize sponsor and investigator workflows
Slide 68: Deploying multi-agentic systems at scale to enhance productivity
68©2026 Labcorp. All rights reserved. Deploying multi-agentic systems at scale to enhance productivity T E C H N O L O G Y A N D I N N O V A T I O N LAB OPTIMIZATION REVENUE CYCLE MANAGEMENT PATIENT SERVICES Orchestrating laboratory operations to improve throughput, quality and scalability Optimizin
Slide 69: Powering the next generation of enterprise capabilities
69©2026 Labcorp. All rights reserved. Powering the next generation of enterprise capabilities T E C H N O L O G Y A N D I N N O V A T I O N AI innovation platform that rapidly scales innovation into competitive advantage Labcorp’s AI platform accelerates enterprise innovation by enabling the secure,
Slide 70: Extracting actionable intelligence from health data
70©2026 Labcorp. All rights reserved. Extracting actionable intelligence from health data T E C H N O L O G Y A N D I N N O V A T I O N Moving beyond episodic diagnostic results to intelligent insights that transform care What is this patient eligible for? Aggregated longitudinal insight Does cross-
Slide 71: Key takeaways
71©2026 Labcorp. All rights reserved. Key takeaways Technology is accelerating revenue growth by improving provider, patient and biopharma experiences AI is embedded across Labcorp to improve productivity and increase operating leverage Automation drives long-term operational performance Labcorp's p
Slide 72: Long-Term Financial Outlook
©2026 Labcorp. All rights reserved. Long-Term Financial Outlook Julia Wang Chief Financial Officer I N V E S T O R D A Y 2 0 2 6
Slide 73: Long-Term Financial Outlook Overview
73©2026 Labcorp. All rights reserved.2026 Labcorp. All rights reserved. L O N G - T E R M F I N A N C I A L O U T L O O K Overview Proven track record of delivering on our financial commitments Durable topline growth driven by clear strategy and focused execution Sustainable margin expansion support
Slide 74: Continued momentum supports strong 2026 outlook
74©2026 Labcorp. All rights reserved. Continued momentum supports strong 2026 outlook L O N G - T E R M F I N A N C I A L O U T L O O K Reiterating our FY 2026 financial guidance1 1. Revenue guidance includes impact from foreign currency translation of 0.4% for enterprise and 1.5% for BLS. Enterpri
Slide 75: Proven track record of driving consistent and profitable growth
75©2026 Labcorp. All rights reserved. Proven track record of driving consistent and profitable growth L O N G - T E R M F I N A N C I A L O U T L O O K Delivering on long-term outlook from 2023 Investor Day 1. Midpoint of FY 2026 guidance previously issued on July 30, 2026; see appendix for more inf
Slide 76: Delivering superior total shareholder returns over time
76©2026 Labcorp. All rights reserved. TSR Over Prior Outlook 12/29/2023 – 08/31/2026 TSR Over Longer-Term 12/31/2019 – 08/31/2026 Delivering superior total shareholder returns over time L O N G - T E R M F I N A N C I A L O U T L O O K LH has outperformed the S&P 500 Healthcare index LH S&P 500 Heal
Slide 77: Disciplined capital deployment fueling growth and shareholder value
77©2026 Labcorp. All rights reserved. Disciplined capital deployment fueling growth and shareholder value L O N G - T E R M F I N A N C I A L O U T L O O K 1. Strategic actions refer to the cash provided by discontinued financing activities from the spin-off of Fortrea in 2023, which was comprised p
Slide 78: We will continue to maintain discipline in our capital deployment strategy
78©2026 Labcorp. All rights reserved. We will continue to maintain discipline in our capital deployment strategy L O N G - T E R M F I N A N C I A L O U T L O O K 2027 – 2029 Illustrative capital deployment: invest into the business, strengthen the portfolio and return to shareholders $6.3B - $7.2B
Slide 79: Durable topline growth powered by organic growth and M&A
79©2026 Labcorp. All rights reserved. Durable topline growth powered by organic growth and M&A L O N G - T E R M F I N A N C I A L O U T L O O K Multiple pathways to drive sustainable long-term growth 5.0% - 8.0% Revenue Growth 2026 – 2029 CAGR Strategic Considerations • Accelerates growth prioritie
Slide 80: Sustainable margin expansion enabled by topline growth and productivity
80©2026 Labcorp. All rights reserved. Sustainable margin expansion enabled by topline growth and productivity L O N G - T E R M F I N A N C I A L O U T L O O K Leveraging advanced technologies to drive innovation and efficiencies 75 - 150 bps Margin Expansion by end of 2029 Capture operating leverag
Slide 81: 2026-2029 Outlook: positioned for continued strong growth
81©2026 Labcorp. All rights reserved. 2026 − 2029 Outlook: positioned for continued strong growth L O N G - T E R M F I N A N C I A L O U T L O O K Compelling revenue growth, margin expansion and cash flow generation driving long-term shareholder value MARGIN EXPANSION 75 - 150 bps by the end of 202
Slide 82: Key takeaways
82©2026 Labcorp. All rights reserved. Key takeaways Proven track record of delivering consistent and profitable growth Durable topline growth and sustainable margin expansion driven by clear strategy and focused execution Compelling long-term outlook with 5%-8% revenue CAGR and 8.5%-11.5% adjusted E
Slide 83: Break
83©2026 Labcorp. All rights reserved. Break
Slide 84: ©2026
©2026 Labcorp. All rights reserved.
Slide 85: ✓ Consistent track record of delivering strong performance ✓ Tremendous growth opportunities ahead ✓
85©2026 Labcorp. All rights reserved. The Case for Labcorp ✓ Consistent track record of delivering strong performance ✓ Tremendous growth opportunities ahead ✓ A differentiated platform powered by science, technology and global scale ✓ Compelling long-term outlook
Slide 86: ©2026
©2026 Labcorp. All rights reserved.
Slide 87: Appendix
©2026 Labcorp. All rights reserved. Appendix
Slide 88: Guidance for 2026
88©2026 Labcorp. All rights reserved. Guidance for 2026 A P P E N D I X 2026 Guidance Low High Revenue Labcorp Enterprise1,2 $14,710 $14,827 Growth3 5.4% 6.3% Diagnostics Laboratories $11,450 $11,532 Growth3 5.3% 6.0% Biopharma Laboratory Services4 $3,269 $3,300 Growth3 5.5% 6.5% Adjusted EPS $18.10